RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Clinical trials for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough nasopharyngeal cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis study tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) in 33 adults with recurrent or metastatic nasopharyngeal cancer that has not responded to prior immunotherapy. The goal is to see if this combo can shrink tumors or control the disease. Partic…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail aims to outdo chemo for tough throat cancer
Disease control Recruiting nowThis Phase 3 trial tests whether combining two drugs, MRG003 and pucotenlimab, works better than standard chemotherapy for people with nasopharyngeal cancer that has returned or spread. About 446 participants will be randomly assigned to receive either the new combo or one of thr…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for advanced nose and throat cancer with combo therapy
Disease control Recruiting nowThis study tests a new drug (YL201) combined with an immunotherapy (toripalimab), with or without chemotherapy (cisplatin), in people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combination is safe and helps control the cancer. About 202 adults …
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for Hard-to-Treat nasopharyngeal cancer: four drug cocktails enter trial
Disease control Recruiting nowThis phase 2 trial tests four different drug combinations in 208 people with advanced nasopharyngeal cancer that has stopped responding to standard treatments, including immunotherapy. The goal is to see which combination best shrinks tumors and delays cancer growth. Participants…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 26, 2026 18:42 UTC